SK 1404

Drug Profile

SK 1404

Alternative Names: SK-1404

Latest Information Update: 21 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanwa Kagaku Kenkyusho
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nocturia

Most Recent Events

  • 23 Feb 2017 Phase-II clinical trials in Nocturia in Japan (PO) (NCT03116191)
  • 01 Aug 2016 Sanwa Kagaku Kenkyusho completes a phase I trial in Nocturia (In volunteers) in United Kingdom (NCT02878096)
  • 01 Jul 2016 Phase-I clinical trials in Nocturia (In volunteers) in United Kingdom (PO) (NCT02878096)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top